NYMOX PHARMACEUTICAL
NASDAQ : NYMX

October 20, 2005 13:47 ET

Nymox Smoking Test Products Receive Wide Media Coverage

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 20, 2005) -

NicAlert™ and TobacAlert™, Nymox Pharmaceutical Corporation's (NASDAQ: NYMX) innovative products for measuring tobacco use or exposure, are currently featured in a wide array of US media spots. The products have been the subject of news reports on US television, in newspaper stories, and in magazine articles. According to market tracking, the exposure has been to over 10 million readers, and many million viewers.

Nymox's NicAlert™ product provides a proven, easy-to-use, on-site means of determining an individual's use of or exposure to tobacco products. The product gives a visual read-out of the level of tobacco use or exposure within minutes and requires no instruments to use. NicAlert™ has received U.S. FDA clearance for medical use for determining an individual's exposure to tobacco products. NicAlert™ uses powerful, one-step patented technology to measure the level of cotinine, a metabolite of nicotine, in urine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product use or exposure.

Nymox also offers TobacAlert™, which is for non-medical uses and can detect second-hand smoke exposure. TobacAlert™ is available at approximately 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information about TobacAlert™ is available at www.tobacalert.com.

In an article in Advance for Nurses (September 2005, article written by Stephanie Adamow), the tobacco exposure reduction efforts led by Dr. Sher Todd of the Tobacco free Babies Project in Reno, Nevada were highlighted. This research has extensively used the Nymox products. According to Dr. Todd, tobacco use and exposure should be routinely assessed as a vital sign like blood pressure or weight, particularly for pregnant women. Research has shown routine assessment of tobacco use or exposure and intervention more than doubled the rate of smoking cessation for pregnant women. NicAlert™ provides their program with an objective biological confirmation of tobacco use or second-hand smoke exposure. Reduction or cessation of tobacco use or second-hand smoke exposure by pregnant women offers both substantial health benefits to both mother and fetus and long-term savings for healthcare programs, providers and payers.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com